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A role for leukotrienes in cyclosporine nephrotoxicity. long-term renal allograft survival [1, 2]. Additionally,
Background. Nephrotoxicity associated with cyclosporine A incorporation of CsA into immunosuppressive protocols
(CsA) administration is characterized by marked renal vaso- has increased the success and scope of transplantationconstriction, interstitial fibrosis, and arteriolar hypertrophy.
of the liver, heart, lung, bone marrow, and pancreas [3].While the molecular mechanisms of CsA toxicity are not well
Because of its efficacy in transplantation, CsA is nowcharacterized, previous studies have demonstrated that altered
arachidonic acid (AA) metabolism plays a role its pathogenesis. being used as clinical therapy in a variety of immunologic
Using a rat renal transplant model, the purpose of this study diseases, in which it shows promise, including glomerulo-
was to examine the effects of CsA on the 5-lipoxygenase (5-LO) nephritis, psoriasis, uveitis, and inflammatory bowel dis-pathway of AA metabolism.
ease [3–5]. Unfortunately, nephrotoxicity continues toMethods. The PVG (RT1c) strain of rats underwent kidney
be an important clinical entity, often limiting the thera-transplantation, and recipients of nonrejecting kidney trans-
plants were treated with either 50 mg/kg/day CsA or vehicle peutic applications of CsA [6–11]. Acute CsA nephrotox-
(N 5 24). To determine the physiologic significance of in- icity is characterized by diminished glomerular filtration
creased leukotriene (LT) production, the peptidoleukotriene rate (GFR) and intense renal vasoconstriction [8]. These
receptor antagonist SKF 106203 was administered to CsA-
hemodynamic alterations are dose dependent and revers-treated animals for six days.
ible with reductions of CsA dosage. In contrast, chronicResults. CsA caused a substantial reduction in glomerular
filtration rate (GFR) in the transplanted rats compared with nephrotoxicity, which is characterized by vascular lesions
the vehicle-treated controls (1.5 6 0.6 vs. 4.1 6 0.8 mL/min/kg, and striped interstitial fibrosis, is irreversible and may
P , 0.05). The reduction in renal function was associated with lead to progressive renal failure and end-stage renal dis-
enhanced urinary excretion of the peptidoleukotriene metabo-
ease [9, 10].lites LTE4 (1431 6 207 vs. 953 6 125 pg/24 h, P , 0.05) and
The molecular mechanisms that cause CsA nephrotox-N-acetyl-LTE4 (4411 6 848 vs. 463 6 70 pg/24 h, P , 0.001).
icity have not been completely characterized. However,LT receptor blockade had a significant protective effect on
renal transplant function in CsA-treated animals (GFR, 4.8 6 alterations in sympathetic nerve activity, the renin-angio-
1.1 vs. 1.7 6 0.9 mL/min/kg, P , 0.05), such that CsA-treated tensin system, and endothelin have all been implicated
animals that received SKF106203 maintained GFR at levels in the pathogenesis of this disorder [12–19]. In addition,similar to controls that never received CsA (4.1 6 0.8 mL/
studies from our group and others have demonstratedmin/kg). Peptidoleukotriene receptor blockade also prevented
abnormalities in arachidonic acid (AA) metabolismthe histomorphological abnormalities caused by CsA, including
tubular vacuolization. caused by CsA and have suggested a role for eicosanoids
Conclusions. These studies identify a critical role for LTs in nephrotoxicity [20–24]. For example, CsA-induced al-
in the pathophysiology of CsA nephrotoxicity and suggest that terations in the cyclooxygenase pathway of AA metabo-
LT antagonists may be useful in preventing CsA-associated
lism leading to enhanced production of thromboxane A2kidney toxicity.
(TXA2) have been well-documented [24, 25]. However,
little is known about the effects of CsA on other pathways
for AA metabolism, such as the 5-lipoxygenase (5-LO)The introduction of cyclosporine A (CsA) into clinical
pathway, which is shown in Figure 1. Similar to TXA2,use has dramatically altered the field of solid organ trans-
leukotrienes (LTs), which are produced by the 5-LOplantation. For example, the widespread use of CsA was
pathway, are potent renal vasoconstrictors, mimickingassociated with significant improvements in one-year and
the hemodynamic effects of CsA [26, 27]. The objective
of this study was to further define the role of 5-LO
products of AA in CsA nephrotoxicity, using a rat kidneyKey words: 5-lipoxygenase pathway, arachidonic acid, peptidoleuko-
triene receptor blockade, tubular vacuolization, kidney toxicity. transplant model. In these studies, we find that CsA
causes a marked and specific enhancement of peptido-Received for publication January 14, 1999
leukotrienes in the kidney, and we provide evidence thatand in revised form August 27, 1999
Accepted for publication January 3, 2000 these lipid mediators contribute to abnormalities of kid-
ney structure and function.Ó 2000 by the International Society of Nephrology
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Fig. 1. The 5-lipoxygenase (5-LO) pathway of arachidonic acid (AA) metabolism.
METHODS hours later. Overall, surgical mortality was less than 10%
and did not differ between the experimental groups.Animals
Inbred male rats of the PVG (RT1c) strain were pur- Drug administration
chased from Bantin and Kingman (Fremont, CA, USA). To induce CsA nephrotoxicity, CsA was administered
These animals were subsequently maintained in the Dur- daily by gavage at 50 mg/kg in an olive oil emulsion, as we
ham VAMC Animal Facility under local and National have described previously [23]. Vehicle control groups
Institutes of Health guidelines. All rats were 8 to 12 weeks received an equal amount of olive oil daily. In a second
old when the studies were performed. set of experiments that were designed to study the effects
of a LT antagonist on CsA nephrotoxicity, CsA-treatedRat renal transplantation
animals also received the peptidoleukotriene antagonist
Rat renal transplants were performed as previously SKF 106203 (3(S)-[(2-carboxyethyl)thio]-3-[2-(8-phenyl-
described [16]. For this nonrejecting isograft model, kid- octyl)phenyl] propanoic acid) at 80 mg/kg or vehicle
neys from PVG rats were transplanted into their litter twice daily by gavage. This dose has previously been
mates. The donor kidney, ureter, and bladder were har- demonstrated to block the renal peptidoleukotriene re-
vested en bloc, including the renal artery with a 3 mm ceptor effectively [28]. In addition, we have previously
aortic cuff and the renal vein with a 3 mm vena caval cuff. demonstrated that the antagonist has no effect on renal
These vascular cuffs were anastomosed to the recipient function in normal rats [28] or mice [29].
abdominal aorta and vena cava, respectively. The total
Measurements of renal transplant functionischemic time averaged 10 to 15 minutes. To create the
urinary anastomosis, donor and recipient bladders were To assess renal isograft function precisely, clearances
attached dome-to-dome. The right native kidney was of inulin and paraaminohippuric acid (PAH) were mea-
removed at the time of transplant, and the left native sured on day 6 following transplantation, as previously
described [28, 30]. On the day of study, the animals werekidney was removed through a flank incision 48 to 72
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Table 1. Effects of cyclosporine (CsA) and peptidoleukotriene receptor blockade on renal function and leukotriene production
Renal Urinary LTE4 Urinary N-acetylRenal LTB4GFR plasma flow excretion LTE4 excretionproduction
Experimental group pg/mg protein pg/24 hml/min/kg
Vehicle 4.160.8 11.562.2 88644 9536125 463699
CsA 50 mg/kg/day 1.660.9a 5.662.0a 56636 14316207c 44116848c
CsA 1 peptidoleukotriene
receptor blocker (SKF 106203) 4.761.1b 13.763.4b Not measured Not measured 67746747c
aP , 0.05 vs. Vehicle
bP , 0.05 vs. CsA
cP , 0.005 vs. Vehicle
anesthetized with Nembutal (20 mg/kg), and a polyethyl- most severe abnormality. A total score was calculated
by adding the individual scores.ene catheter (PE-240) was inserted into the trachea to
facilitate spontaneous respiration. The right carotid ar-
Measurements of leukotriene productiontery was cannulated to permit periodic sampling of arte-
rial blood and measure arterial blood pressure (BPM- On day 4 following transplantation, rats were placed
8802; Caldwell Systems, Rougemont, NC, USA). The in metabolic cages, and urine was collected over 24 hours
jugular vein was cannulated, and a volume of normal in a cooling chamber. At the end of the collection period,
saline equal to 1.0% of body weight was infused to re- the urine was frozen and stored at 2708C until LT con-
place surgical losses. Following saline infusion, priming centrations were measured. LT metabolites in urine were
doses of 14C-inulin and glycyl-3H-PAH (Amersham, Ar- extracted and separated by high-performance liquid chro-
lington Heights, IL, USA) in saline were given followed matography (HPLC) prior to quantitation by radioimmu-
by a continuous infusion at a rate of 0.05 mL/100 g/min. noassay (RIA) as described previously [28], with some
The ureter of the transplant kidney was cannulated with modifications. Samples were acidified and applied to C-18
a PE-10 catheter. After a 45-minute equilibration period, columns preconditioned with methanol and water. After
urine was collected for two consecutive 30-minute clear- washing, the samples were eluted with a 70% solution
ance periods. Arterial blood samples were obtained at of acetonitrile in water and evaporated to dryness under
the midpoint of each urine collection. Tritium and 14C nitrogen and then reconstituted in a 1:1 solution of aceto-
radioactivity were measured in blood and urine with nitrile and 2.5 mmol/L trifluoroacetic acid. To separate
a dual-channel Isocap 300 liquid scintillation counter LTs, a Pecosphere HS3-C18 cartridge (Perkin-Elmer
(Nuclear Chicago, Chicago, IL, USA). Clearances of inu- Corp., Norwalk, CT, USA) was used. Samples and LT
lin and PAH were calculated by standard formulas. standards (Advanced Magnetics Inc., Cambridge, MA,
USA) were injected onto the column and eluted with a
Evaluation of kidney transplant histomorphology linear gradient from 100% 2.5 mmol/L trifluoroacetic
acid to 100% acetonitrile over eight minutes at a flowFollowing the renal hemodynamic studies, a portion
of the transplanted kidney was removed and placed in rate of 3 mL/min. Elution of LTs from the column was
monitored by absorbance at wavelength 280 nm with a10% buffered formalin. After formalin fixation, the kid-
ney tissue was sectioned and stained with hematoxylin programmable multiwavelength ultraviolet spectropho-
tometer (Waters Associates, Milford, MA, USA). In thisand eosin (HE) and periodic acid-Schiff (PAS) stains.
The slides were reviewed by a renal pathologist (P.R.) HPLC system, the LT standards for LTE4 and its major
urinary metabolite, N-acetyl-LTE4, were resolved in twowho was masked to the treatment groups and graded as
described previously [30]. The severity of the vascular, closely eluting absorbance peaks. All separations were
performed at ambient temperature. Collected fractionstubular, and interstitial abnormalities were each graded
separately using a semiquantitative scale from 0 to 41, were evaporated to dryness under nitrogen and reconsti-
tuted in appropriate buffer for quantitation by RIA,where 0 was no abnormality, and 41 represented the
c
Fig. 2. Effects of peptidoleukotriene receptor blockade on renal histopathological changes in rats treated with cyclosporine A (CsA). (A)
Representative photomicrograph of an HE-stained section of a renal isograft from a rat that was treated with CsA 50 mg/kg/day for six days. The
major structural abnormality in these kidneys is diffuse vacuolization of proximal tubule cells that can been seen throughout the section. (B) A
similarly stained section of a renal isograft from a rat that received CsA along with the peptidoleukotriene receptor antagonist SKF106203. Kidney
histomorphology was virtually normal in these animals and not significant from that of renal isografts from animals that never received CsA (data
not shown).
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as described later in this article. Using this technique, mean of the values measured during at least two clear-
ance periods. For most comparisons between groups, sta-recovery of standards ranged from 40 to 60%.
Following renal hemodynamic studies, the transplant tistical significance was assessed using an unpaired t-test.
The Mann–Whitney U-test was used in the comparisonskidney was rapidly removed, and a portion was weighed
and placed in Krebs buffer at 48C. The kidney was then of the histopathologic scores.
bisected, and a central slice was obtained. Cortex was
separated from medulla by macrodissection. Portions of
RESULTS
cortex were homogenized and suspended in 2 mL of iced
The effect of CsA administration on renal isograftKreb’s buffer containing 10 mmol/L concentrations of
function on day six after transplantation is shown inthe calcium ionophore A23187. The suspensions were
Table 1. CsA caused marked reductions in clearances ofincubated for 30 minutes at 378C in 95% O2/5% CO2.
inulin and PAH. In this model, CsA treatment reducedSamples were centrifuged at 2000 r.p.m. for 10 minutes
GFR by approximately 60% (1.6 6 0.9 mL/min/kg in theat 48C, and the supernatants were stored at 2708C until
CsA-treated group vs. 4.1 6 0.8 mL/min/kg in vehicle-eicosanoids were measured, as described later in this
treated controls, P , 0.05); renal plasma flow (RPF) wasarticle. The tissue pellet was resuspended in 0.5 mL of
reduced to a similar extent (5.6 6 2.0 mL/min/kg withcold Kreb’s buffer, and the protein concentration was
CsA vs. 11.5 6 2.2 mL/min/kg in controls, P , 0.05).measured using the Coomassie Brilliant Blue dye-bind-
As an index of renal LT production in vivo, we mea-ing assay.
sured urinary excretion of LTE4 metabolites. As shown
in Table 1, CsA produced a dramatic, nearly tenfoldRadioimmunoassays
increase in excretion of N-acetyl LTE4 metabolites fromConcentrations of LTB4 in supernatants from incuba-
463 6 99 pg/24 h in vehicle-treated animals to 4411 6tions of kidney homogenates were measured by direct
848 pg/24 h in the rats that received CsA (P , 0.005).RIA as previously described [28] using a polyclonal anti-
An increase in excretion of LTE4 was also observed. Wesera (Amersham). Samples (measured in duplicate) and
also examined the effect of CsA on the production ofstandards (measured in triplicate) were incubated with
LT B4 in cortical homogenates following stimulation withknown quantities of [3H]-LTB4 and antisera at 258C for
A23187. Unlike its effect on the peptidoleukotrienes,two hours. The concentration of unlabeled LTB4 that
CsA administration had no significant effect on renalinhibited 50% binding of [3H]LTB4 tracer was 42.7 pg/
production of LTB4 (56 6 36 vs. 88 6 44 pg/mg protein/100 mL (mean standard error of 4 assays), and the lower
min, P 5 NS).limit of delectability was 0.5 pg/100 mL. For measure-
To test whether augmented LT production contributesment of peptidoleukotriene excretion in urine, individual
to reduced renal function in CsA-treated animals, ratsHPLC fractions were collected based on elution of au-
with renal isografts were also given 50 mg/kg/day of CsAthentic LTE4 and N-acetyl-LTE4 standards. Concentra-
along with 80/mg/kg/day of the specific peptidoleuko-tions of urinary LTE4 and N-acetyl-LTE4 in experimental
triene receptor antagonist SKF 106203 or its vehicle. Asspecimens were then measured using a polyclonal anti-
shown in Table 1, in the group that received vehicle, CsAbody that cross-reacts with a series of peptidoleuko-
significantly reduced renal isograft function. In contrast,trienes, including LTE4 and N-acetyl-LTE4 [18]. The con-
treatment with the peptidoleukotriene antagonist pre-centration of unlabeled LTE4 that inhibited 50% binding
served GFR at levels that were not different from iso-of [3H]LTE4 tracer was 284 6 19 pg/100 mL (mean stan-
graft controls not treated with CsA. The LT receptordard error of 3 assays), and the lower limit of delectability
antagonist had a similar beneficial effect on RPF. Thesewas 8 pg/100 mL. After incubation for two hours at 48C,
effects appeared to be related to blockade of the peptido-unbound eicosanoids were removed from the mixture
leukotriene receptor and not to an alteration in CsAwith a suspension of dextran-coated activated charcoal.
metabolism or inhibition of peptidoleukotriene produc-Sample concentrations were determined by a standard
tion, as the peptidoleukotriene receptor antagonist didcurve in which the logarithm of the concentration is
not prevent the enhanced excretion of N-acetyl LTE4plotted versus the log of the B/Bo value. Results were
associated with CsA administration (Table 1).expressed as pg/min/mg protein. We found that the cross-
To determine the effect of CsA on histomorphologyreactivity of the LTB4 antibody (Amersham) was less
in renal isografts, structural abnormalities were exam-than 1% with LTC4, LTD4, and LTE4. Cross-reactivity
ined and graded by a pathologist (P.R.) who was maskedof the polyclonal peptidoleukotriene antibody with LTB4
to the treatment groups. As can be seen in the represen-was also less than 1%.
tative photomicrographs shown in Figure 2, the primary
Statistical analysis histologic abnormality observed in animals treated with
CsA was marked tubular vacuolization. This abnormalityData are presented as mean 6 SEM. For the hemody-
namic studies, data points for each animal represent the has been previously reported to be a characteristic fea-
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renal dysfunction in this model [23]. Perico et al demon-
strated a similar effect of a thromboxane synthase inhibi-
tor in rats with CsA nephrotoxicity [20]. In renal trans-
plant patients treated with CsA, we found that urinary
excretion of thromboxane metabolites was enhanced.
Additionally, treatment with a thromboxane synthase
inhibitor produced transient increases in RPF and GFR
in 8 of 10 patients [34]. Thus, in animal models and in
human renal transplant recipients, dysregulation of the
cyclooxygenase pathway of AA metabolism contributes
to the pathogenesis of CsA nephrotoxicity.
We now provide evidence that abnormal production
of 5-LO metabolites of AA causes kidney dysfunction
and injury in CsA nephrotoxicity. As shown in Figure 1,
Fig. 3. Histopathological grading of rat renal isograft sections. The AA that is released from membrane phospholipids by
severity of the histopathological abnormalities observed in renal iso-
phospholipases is converted by 5-LO into LTA4. Thegrafts from the experimental groups were graded as described. The
degree of histopathological abnormality was significantly reduced in activity of 5-LO in intact cells is dependent on 5-LO
the group that received CsA 1 SKF 106203 (j) compared with the activating protein or FLAP. LTA4 is further metabolizedgroup that received CsA alone (h). Moreover, there was no significant
by one of two pathways: It is converted to LTB4 by thedifference in histopathological score between the group that received
CsA 1 SKF 106203 and the group that received olive oil vehicle without enzyme LTA4 hydrolase, or it is metabolized along the
CsA ( ) (*P , 0.01). peptidoleukotriene pathway, beginning with the addition
of glutathione to form LTC4 by the enzyme LTC4 syn-
thase. This divergence of LTA4 metabolism has func-
tional significance. LTB4 is a potent chemotactic agentture of CsA toxicity in the rat [31]. To determine whether
that promotes neutrophil aggregation, adhesion and en-improved renal function seen with peptidoleukotriene
zyme release [27], while the peptidoleukotrienes (LTC4,receptor blockade was associated with changes in kidney
LTD4, LTE4) are potent vasoactive substances [26, 27,histology, we compared the histomorphology of renal
35]. Infusions of LTC4 reduce GFR by increasing arterio-isografts from the CsA-treated rats that received
lar vasoconstriction and diminishing the glomerular ul-SKF106203 or its vehicle. As illustrated in the photomi-
trafiltration coefficient [26]. These hemodynamic effectscrographs in Figure 2, renal architecture was virtually
of peptidoleukotrienes mimic the effects of CsA on renalnormal in the animals that received SKF106203. The
hemodynamics. Furthermore, in cell culture models,significant degree of tubular vacuolization that was seen
peptidoleukotrienes stimulate synthesis of collagen andin the vehicle group was not observed in the group that
extracellular matrix proteins [36, 37]. The abnormal ac-received the LT-receptor antagonist. As shown in Figure
cumulation of collagen and matrix proteins in the renal3, these differences were reflected by a significant reduc-
interstitium is one of the defining features of chroniction in the semiquantitative scoring for histologic abnor-
CsA nephrotoxicity.malities in the SKF106203 group (0.3 6 0.2) compared
In a rat renal transplant model, we find that the admin-with controls (1.4 6 0.2, vs. SKF106203). The histologic
istration of CsA causes a marked stimulation of peptido-grade of kidney grafts from CsA-treated animals that
leukotriene production, reflected by enhanced excretionalso received SKF106203 was not different from kidneys
of peptidoleukotriene metabolites in urine. The adminis-in animals that had never received CsA.
tration of CsA results in an exclusive stimulation of pepti-
doleukotriene production; LTB4 production is not sig-
DISCUSSION nificantly affected. This suggests a direct effect of CsA
on the expression and/or activity of LTC4 synthase. Al-Alterations in the renal sympathetic nervous system,
the renin angiotensin system, endothelin, and nitric oxide ternatively, stimulation of LT production by CsA may
be confined to cell types that primarily synthesize pepti-have all been implicated in the pathogenesis of CsA
nephrotoxicity [12–19, 32, 33]. In addition, we and others doleukotrienes and not LTB4. In support of this latter
hypothesis are observations by our group and others thathave previously demonstrated that alterations in synthe-
sis of the AA metabolite TXA2 may mediate renal hemo- the administration of CsA is associated with a significant
accumulation of macrophages in the kidney [23, 38, 39].dynamic actions of CsA [20–24]. For example, in a rat
model, CsA nephrotoxicity is accompanied by enhanced Activated macrophages synthesize large quantities of
LTC4, but very little LTB4 [27].production of thromboxane metabolites by the kidney
[24]. We subsequently found that the administration of A physiological role for enhanced peptidoleukotriene
production in CsA toxicity was established by the obser-a thromboxane receptor antagonist partially abrogated
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